JACC

Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity

Retrieved on: 
Sunday, April 7, 2024
Uric acid, Urinary tract infection, Anaphylaxis, Myocardial infarction, Common, Bronchitis, Patient, Atherosclerosis, FAHA, Cleveland Clinic, Bempedoic acid, Ezetimibe, Therapy, Anemia, Pain, MACE, Sinusitis, ACC, FOMA, FNLA, FACC, Obesity, Cardiovascular disease, Esperion Therapeutics, Abdominal pain, Risk, Gout, Spasm, Woman, American College, Body mass index, ESPR, Back pain, Outcome, ATP, Safety, Fatigue, Arthralgia, ANN, Angioedema, Kidney, Journal, Constipation, University, Adverse event, Pregnancy, CLEAR, Rash, MPH, Rupture, FDA, Molina Healthcare, JACC, Hypersensitivity, Health, Circulatory system, Tablet, CVD, Incidence, Diarrhea, Fetus, Gallstone, Diet, Excipient, Upper respiratory tract infection, Dietary supplement

ANN ARBOR, Mich., April 07, 2024 (GLOBE NEWSWIRE) -- Esperion (Nasdaq: ESPR) today announced the presentation of results from three pre-specified subgroups from CLEAR Outcomes at the 2024 American College of Cardiology’s Annual Scientific Sessions (ACC.24): women, Hispanic/Latinx, and patients with obesity. These results align with the American College of Cardiology’s robust diversity, equity and inclusion programs to drive cultural change across the profession and ensure that the cardiovascular care team is as diverse as the patients they care for and that all patients are represented in cardiovascular research. The data also reinforce the mission of the ACC: transforming cardiovascular care for all.

Key Points: 
  • “Bempedoic acid is the only FDA approved non-statin LDL lowering therapy to demonstrate reductions in MACE in both primary prevention and secondary prevention patient populations.
  • The Hispanic population is the largest ethnic minority in the U.S., yet is a population historically underrepresented in clinical trials.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Retrieved on: 
Saturday, April 6, 2024
MB, TGS, High, Science, CH.B, Risk, Research, American College, MACE, Professional corporation, IPE, JACC, Pharmaceutical industry

DUBLIN, Ireland and BRIDGEWATER, N.J., April 06, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted two data presentations at ACC.24 describing the effects of VASCEPA®/VAZKEPA® (icosapent ethyl) on reducing MACE (Major Adverse Cardiovascular Events) in patients with baseline high or low Lipoprotein(a) [Lp(a)] levels, as well as reducing the risk of cardiovascular (CV) events in patients irrespective of baseline LDL-C level. The REDUCE-IT analysis results relating Lp(a) concentrations with CV risk were also published online today in the Journal of the American College of Cardiology (JACC).

Key Points: 
  • There are no treatments currently approved to reduce residual CV risk on top of contemporary medical therapy in patients with high Lp(a) levels.
  • In this subanalysis, there were 7,026 REDUCE-IT patients with baseline Lp(a) data and a median Lp(a) value of 11.6 (Q1-Q3: 5.0-37.4) mg/dL.
  • Importantly, the treatment benefit of IPE was evident across subgroups with both high (≥50 mg/dL) and low (
  • Limitations are that randomization was not stratified by baseline LDL-C, however, baseline characteristics were similar among the two baseline LDL-C subgroups.

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

Retrieved on: 
Thursday, April 4, 2024
Diabetic cardiomyopathy, Patient, Journal, Diabetes, American College, Treatment, Therapy, Safety, ACC, JACC, Pharmaceutical industry

The presentation at ACC will also include important data on progression to overt heart failure and other secondary outcome measures.

Key Points: 
  • The presentation at ACC will also include important data on progression to overt heart failure and other secondary outcome measures.
  • AT-001 treatment prevented progression to overt heart failure in patients with DbCM as compared to placebo (p=0.0285).
  • The oral presentation at ACC will be followed by simultaneous publication of the study results in the Journal of the American College of Cardiology Journal (JACC).
  • A Selective Aldose Reductase Inhibitor (AT-001) For the Treatment of Diabetic Cardiomyopathy: Primary Results of the Phase 3 Randomized Controlled ARISE-HF Study
    Monday, April 8, 2024, 8:30 – 9:45 am ET, Main Tent (Hall B1)

Large, Real-world Studies Demonstrate Continued Excellent Outcomes for Patients Receiving Edwards SAPIEN TAVR

Retrieved on: 
Monday, March 11, 2024
Health, Medical Devices, Surgery, Clinical Trials, Research, Science, Cardiology, Registry, CRT, Aortic stenosis, TVT, Patient, Journal, Stroke, Mortality, Ultra, Oakland University, MD, Cardiovascular disease, American College, TAVR, Arrest, JACC, PVL, Medical imaging

Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.

Key Points: 
  • Edwards Lifesciences (NYSE: EW) announced today at Cardiovascular Research Technologies (CRT) 2024 the compelling results from two large, real-world studies based on TVT Registry data that demonstrated continued excellent outcomes for patients treated with the Edwards SAPIEN valve platform.
  • In a second study presented during the late-breaking clinical trials session, small Edwards SAPIEN TAVR valves demonstrated equally excellent outcomes at 3 years as compared to larger SAPIEN TAVR valve sizes.
  • The study found that all Edwards TAVR platforms demonstrated excellent PVL results.
  • An analysis of 8,100 propensity matched patients across more than 800 sites in the United States found that patients treated with a 20mm Edwards SAPIEN valve demonstrated excellent all-cause mortality and stroke outcomes at 3-years, equivalent to those receiving 23, 26 and 29mm SAPIEN valve sizes.

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Tuesday, February 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

Retrieved on: 
Tuesday, February 6, 2024
Inflammation, Growth, Liver cancer, Immunity, Immunotherapy, Research, JACC, Therapy, Prevalence, Tan, Metabolic syndrome, PNAS, MOA, JAMA Oncology, Sorafenib, Fibrosis, Bevacizumab, Immunogenic cell death, Laboratory, ICIS, Metabolism, Pembrolizumab, Neoplasm, MASH, Nivolumab, Hepatology, Liver, Cancer

The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.

Key Points: 
  • The STAM™-HCC/IO+ mouse is a model that allows stable evaluation of the growth of multiple target lesions originating from the liver over a certain period.
  • Furthermore, it can be used for testing molecular target drugs and immune checkpoint inhibitors, and for other therapeutic targets while performing stable drug efficacy evaluations.
  • As the prevalence of liver cancer increases, it is anticipated that SMC Laboratories' STAM™-HCC/IO+ mouse will greatly contribute to the development of therapeutic drugs for liver cancer in the future.
  • Liver cancer is the fourth most common type of cancer in the world (Huang DQ et al, Nature Reviews Gastroenterology & Hepatology, 18, 223-238, 2021).

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

Retrieved on: 
Wednesday, January 24, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Genetics, Nuclear medicine, Entrepreneurship, Artificial intelligence, Patient, Internal medicine, Research, American College of Physicians, MD, Cardio, Emory University, JACC, Innovation, University, Algorithm, Journal of Clinical Investigation, FACC, ACP, ACC, Journal, NIH, Cardiovascular disease, Bachelor of Science, Hospital, Society for Vascular Surgery, Mount Sinai School, American College, Growth, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.
  • The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company’s continued growth and market expansion.
  • “I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” said Dr. Ramjee.
  • Dr. Ramjee will also work to raise awareness of Cardio Diagnostics’ innovative technologies and their potential to improve patient care.

NanoPhoria Bioscience Publishes Groundbreaking Study in Major Cardiology Journal

Retrieved on: 
Tuesday, January 2, 2024
Research, Medical Devices, Surgery, Clinical Trials, Cardiology, Other Health, Biotechnology, General Health, Health, Science, Blood pressure, Heart rate, FESC, JACC, Injection, Disease, FACC, Massachusetts General Hospital, MD, Doctor of Philosophy, Heart failure, Inhalation, Animal, Cerebral edema, LTCC, American College, Patient, Facial muscles, Harvard Medical School, Journal, Medical device

NanoPhoria srl, a pre-clinical stage biotech company, is pleased to announce today the publication of a groundbreaking study in the field of cardiology, conducted using a clinically relevant pig model of heart failure.

Key Points: 
  • NanoPhoria srl, a pre-clinical stage biotech company, is pleased to announce today the publication of a groundbreaking study in the field of cardiology, conducted using a clinically relevant pig model of heart failure.
  • This significant piece of preclinical research, titled “Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure,” was published by our co-founders in the Journal of the American College of Cardiology (JACC), a prominent peer-reviewed medical journal.
  • Results confirming the therapeutic effect recapitulated ex vivo in cardiac myofibrils and biopsies from treated heart failure animals.
  • “Additionally, our research showcases a major advancement in the field of heart disease treatment.

PlaqueTec recruits first ten patients in BIOPATTERN trial

Retrieved on: 
Wednesday, November 29, 2023
Stem Cells, Medical Supplies, Practice Management, FDA, Physical Therapy, Diabetes, Managed Care, General Health, Other Health, Radiology, Pharmaceutical, Oncology, Medical Devices, Hospitals, Health Technology, Biometrics, Genetics, Fitness & Nutrition, Cardiology, Biotechnology, Health, Safety, Mallinckrodt, Royal Bournemouth Hospital, MHRA, Disease, World Heart Federation, Risk, Protein, CAD, Patient, Medicine, Research fellow, Death, NHS, Bristol Royal Infirmary, LBS, Royal Papworth Hospital, Coronary artery disease, Harvard Medical School, CVD, Health care, Liquid biopsy, JACC, Pharmaceutical industry, Medical imaging, Medical device

PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.

Key Points: 
  • PlaqueTec, a company identifying endotype-specific biomarkers to advance precision medicine for coronary artery disease (CAD), today announced that it has received the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approval to continue its BIOPATTERN trial following recruitment of the first ten patients with CAD.
  • The BIOPATTERN trial will use PlaqueTec’s proprietary blood sampling device, the Liquid Biopsy System™ (LBS), to collect samples at multiple sites along a patient’s diseased coronary artery.
  • Thousands of proteins and other blood molecules will be measured in each sample, enabling the assessment of trans-plaque gradients between samples.
  • The trial aims to recruit 300 patients with established CAD who have been scheduled for a coronary angiogram.

Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)

Retrieved on: 
Tuesday, November 7, 2023
MCF, Quality of life (healthcare), HIV disease progression rates, CMP, ID, Amyloid cardiomyopathy, Echocardiography, MRI, MPH, Health, Troponin, Cardiology, Cardiac amyloidosis, GLS, Journal, BWH, University, Patient, N-terminal prohormone of brain natriuretic peptide, Amyloidosis, Heart, LV, Publication, JACC, PET, Quality of life, TBR, Editorial, PET/CT, CAA, Amyloid, Harvard Medical School, ATTR, Devouring Radiant Light, Literature, Alys, Diagnosis, ECV, SAN, Medical imaging, Hospital, AL amyloidosis, Medicine, Iodine, Brigham

124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.

Key Points: 
  • 124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.
  • The manuscripts from Brigham and Women’s Hospital (BWH) and from the University of Tennessee Graduate School of Medicine were published in the Journal of American College of Cardiology – Cardiovascular Imaging (JACC CV Imaging).
  • The manuscripts, entitled “Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir” and “Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study,” have been published online.
  • These studies suggest that 124I-evuzamitide is a promising novel radiotracer to detect and quantify cardiac amyloid in multiple types of amyloidosis.